Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study.
Kus F, Can Guven D, Yildirim HC, Akagunduz B, Karakaya S, Sutcuoglu O, Chalabiyev E, Akyildiz A, Koksal B, Sahin YB, Karaca E, Kavruk OA, Zor NT, Sirvan F, Yazici O, Yalcin S. Kus F, et al. Among authors: chalabiyev e. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241280273. doi: 10.1177/15347354241280273. Integr Cancer Ther. 2024. PMID: 39367737 Free PMC article.
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma.
Yildirim HC, Bayram E, Chalabiyev E, Majidova N, Avci T, Güzel HG, Kapar C, Uzun M, Perkin P, Akgül F, Yildirim SS, Sali S, Yildiz A, Kazaz SN, Hendem E, Arcagok M, Tufan G, Yildirim U, Akgul OF, Arslan Ç, Taban H, Sahin E, Caglayan M, Esen R, Öksüzoğlu B, Guven DC, Kaplan MA, Araz M, Basaran M, Cubukcu E, Gokmen E, Cicin I, Algin E, Semiz HS, Tural D, Ozturk B, Erdogan AP, Sari M, Kara O, Erman M. Yildirim HC, et al. Among authors: chalabiyev e. J Chemother. 2024 Sep 10:1-12. doi: 10.1080/1120009X.2024.2403051. Online ahead of print. J Chemother. 2024. PMID: 39257075
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer.
Yildirim HC, Buyukkor M, Kavgaci G, Celik BŞ, Yucel KB, Dursun B, Chalabiyev E, Yilmaz F, Yildirim SS, Kus F, Tay F, Gecgel A, Koksal B, Guven DC, Yazici O, Urun Y, Ozet A, Gokmen E, Oksuzoglu B, Aksoy S. Yildirim HC, et al. Among authors: chalabiyev e. Medicine (Baltimore). 2024 Jul 26;103(30):e38828. doi: 10.1097/MD.0000000000038828. Medicine (Baltimore). 2024. PMID: 39058877 Free PMC article.
Sirolimus experience in adult patients with vascular malformations.
Akyildiz A, Ismayilov R, Guven DC, Yildirim HC, Tatar OD, Kus F, Chalabiyev E, Turker FA, Dizdar O, Yalcin S, Gullu HI. Akyildiz A, et al. Among authors: chalabiyev e. Vascular. 2024 Mar 24:17085381241241853. doi: 10.1177/17085381241241853. Online ahead of print. Vascular. 2024. PMID: 38523367
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
Yildirim HC, Kapar C, Koksal B, Seyyar M, Sanci PC, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, Keskinkilic M, Ozaskin D, Avci T, Gunes TK, Arcagok M, Topal A, Keskin GSY, Kavgaci G, Yildirim N, Celayir OM, Avci N, Aslan F, Alkan A, Erciyestepe M, Cengiz M, Pehlivan M, Gulmez A, Beypinar I, Basoglu Tuylu T, Kayikcioglu E, Chalabiyev E, Turhal S, Guzel HG, Ayas E, Sahbazlar M, Dulgar O, Demir H, Yavuzsen T, Bayoglu V, Kivrak Salim D, Ozturk B, Ozdemir F, Kara O, Oksuzoglu B, Bal O, Demirci NS, Yilmaz M, Cabuk D, Aksoy S. Yildirim HC, et al. Among authors: chalabiyev e. J Chemother. 2025 Feb;37(1):69-75. doi: 10.1080/1120009X.2024.2330835. Epub 2024 Mar 18. J Chemother. 2025. PMID: 38497444
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Yıldırım HÇ, et al. Among authors: chalabiyev e. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. Int J Clin Oncol. 2024. PMID: 38310597
Advances in the Early Detection of Hepatobiliary Cancers.
Yıldırım HÇ, Kavgaci G, Chalabiyev E, Dizdar O. Yıldırım HÇ, et al. Among authors: chalabiyev e. Cancers (Basel). 2023 Jul 30;15(15):3880. doi: 10.3390/cancers15153880. Cancers (Basel). 2023. PMID: 37568696 Free PMC article. Review.
16 results